Background {#Sec1}
==========

Epidemiology {#Sec2}
------------

Traumatic brain injury (TBI) is one of the main problems in the public health system due to its magnitude and clinical and social consequences \[[@CR1]\]. It is the main cause of disability in young adults, with an estimated 2 million visits to emergency services in the United States in 2009 \[[@CR2]\]. In low-income countries, the rate of TBI, especially due to motor vehicles, are \> 80% of all cases, leading to higher costs and disabilities \[[@CR3], [@CR4]\]. In Brazil, the incidence of TBI is 65.6/100,000 inhabitants per year; however, this incidence appears to be underestimated due to the lack of methodology or inadequate documentation of medical records \[[@CR5]\].

Clinical and functional problems due to TBI {#Sec3}
-------------------------------------------

TBI is an alteration in brain function, or other evidence of brain pathology, caused by an external cause \[[@CR6]\]. The trauma can result in long-lasting disability, even in people with mild TBI \[[@CR7]\].

Long-term neurological and cognitive deficits are expected, including a variety of cognitive impairments, such as in learning, executive function including working memory \[[@CR8], [@CR9]\] and verbal fluency \[[@CR10]\], reaction time, perceptual organization \[[@CR11]\], attention, verbal and visual episodic memory \[[@CR12], [@CR13]\], depression, anxiety \[[@CR8], [@CR9], [@CR14]\], fatigue, sleep disorders, and attention deficit \[[@CR15]\]. Those symptoms are associated with loss of functionality,absence from work, and personal and social privations \[[@CR16], [@CR17]\].

Rationale for the photobiomodulation using low-level laser therapy (LLLT) in patients with TBI {#Sec4}
----------------------------------------------------------------------------------------------

Considerable evidence has shown that the brain has an extensive ability of reorganization after damage \[[@CR18]\]. Non-invasive brain stimulation (NIBS) can modulate brain plasticity after trauma through increasing synaptic strength, modulating neurotransmitters, and modifying neural networks \[[@CR18]--[@CR21]\]. LLLT is a technique of NIBS that the irradiation of specific infrared wavelengths is able to penetrate deeply into the brain \[[@CR22]\]. These effects produce many biological responses, such as affecting the forming of adenosine triphosphate (ATP), increasing deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), releasing nitric oxide (NO), cytochrome c oxidase (CCO), regulating reactive oxygen species (ROS), and modifying intracellular organelle membrane activity particularly in mitochondria, calcium flux, and stress proteins \[[@CR23]--[@CR25]\]. LLLT produces a shift toward higher oxidation in the overall cell redox potential \[[@CR26]\] and briefly increases the level of ROS \[[@CR27]\]. This change in the redox state of the mitochondria regulates several transcription factors \[[@CR28]\]. These include redox factor-1 (Ref-1), cAMP response element (CREB), activator protein 1 (AP-1), p53, nuclear factor kappa B (NF-jB), hypoxia-inducible factor (HIF-1), and HIF-like factor \[[@CR28]\]. The activation and regulation of redox-sensitive genes and transcription factors are thought to be caused by ROS induced from LLLT \[[@CR27]\]. In turn, both ATP levels and blood flow increase, improving oxygenation found in damaged areas of the brain \[[@CR28]\]. In animal models, LLLT has been investigated as an alternative treatment for brain injury, increasing neurogenesis after TBI \[[@CR29]\] and showing a protective effect for stroke \[[@CR30]\] and benefits for acute ischemic stroke, acute myocardial infarction, injured peripheral nerves, and spinal cord injury \[[@CR31]--[@CR33]\]. Previous studies showed the safety of photobiostimulation in humans \[[@CR34]\], including promising interventions for acute stroke \[[@CR34]\], TBI \[[@CR17], [@CR35]--[@CR37]\], and dementia \[[@CR38]\]. However, to date, just one open-label clinical trial studies the effect of LED therapy on improving cognitive function in patients with TBI \[[@CR37]\]. Likewise, no randomized controlled trial studied the short-term and long-term effects of LLLT on the cognition of closed TBI patients.

Objective {#Sec5}
---------

The aim of this study is to evaluate inhibitory attentional control after 18 sessions of active LLLT and compare with the placebo group (sham LLLT). Our exploratory analysis will evaluate verbal and visuospatial episodic memory, executive functions (working memory, verbal and visuospatial fluency, attentional processes), and anxiety and depressive symptoms.

Methods {#Sec6}
=======

Study design {#Sec7}
------------

This is a prospective, multicenter, randomized, parallel placebo-controlled trial that will be conducted at the Clinics Hospital, University of São Paulo (HC-FMUSP) and Salgado Institute, Londrina, Brazil. The protocol is registered on clinicaltrials.org (number NCT02393079). The trial will follow the CONSORT (Consolidated Standards of Reporting Trials) guidelines as well as SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines (Fig. [1](#Fig1){ref-type="fig"}). Figure [2](#Fig2){ref-type="fig"} provides all information about patient enrollment, interventions, and follow-ups.Fig. 1Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT): enrollment, assessment, interventions, and data collection. BDI-II: Beck Depression Inventory, 2^nd^ edition; BAI: Beck Anxiety Inventory; TMT A and B: Test Trail Making form A and B; COWAT: Controlled Oral Word Association Test; SNL: Sequence of Numbers and Letters; DSST: Digit Symbol Substitution Test; RAVLT: Rey Auditory Verbal Learning TestFig. 2Flowchart of the LLLT study

Eligible participants {#Sec8}
---------------------

### Inclusion criteria {#Sec9}

Patients of both genders;Age range 18--60 years;Glasgow Coma Scale (GCS) ≤ 12 at admission in the emergency room;Computer tomography (CT) or magnetic resonance imaging (MRI) consistent with closed TBI, including intracranial hematoma, subdural hematoma, epidural hematoma, diffuse axonal injury, hemorrhagic contusion, and subarachnoid hemorrhage;Loss of consciousness ≥ 30 min;Post-traumatic amnesia of ≥ 24 h;Outpatients with \> 6 months TBI;Signed informed consent.

### Exclusion criteria {#Sec10}

Metal implant or device in the brain or scalp;Uncontrolled epilepsy;Non-consent sign;Portuguese not their first language;Non-comprehension and/or not able to follow instructions.

### Recruitment {#Sec11}

The patients will be contacted and invited to participate before or after their regular appointment at the Neurotrauma Outpatient Clinics at the HC-FMUSP or by a contact list of provided by the acute Neurotrauma Inpatient Section at the HC-FMUSP. The patients will give verbal consent before attending their first consent visit.

Study intervention {#Sec12}
------------------

### Standard care {#Sec13}

All patients will keep their clinical follow-up at the Neurotrauma Outpatient Clinics at HC-FMUSP or at Salgado Institute, Brazil, independently of the study group assignment or decision of dropping out. A trained research nurse and a psychologist introduced the trial to patients informing them of the principles, objectives, and safety/harm. A trained physical therapist will also conduct and follow the patients along the trial.

All information related to patients (i.e. data analysis, anthropometrical measures, reports, and other relevant information) will be stored in locked file cabinets in areas with limited access. These files will be identified with a code ID and only researchers of this study will have access to this information.

### LLLT intervention {#Sec14}

Two optical and identical devices (helmets) will be used for the intervention (Fig. [3](#Fig3){ref-type="fig"}). For the active optical device, a helmet configured with 13 sets of LEDs at a 632-nm wavelength will distribute a total optical radiation of 830 mW over the skull surface. The skull area receiving irradiation is approximately 400 cm^2^ during 30 min, in which the total expected dose per session is 3.74 J/cm^2^. However, only 3.1% of this energy reaches the gray matter \[[@CR39]\].Fig. 3**a** Two identical helmets, active and sham stimulation. **b** The inside view of the active LLLT helmet

The rationale follows: optimal wavelength penetration within biological tissues, occurs with a wavelength range of 600--1000 nm \[[@CR40]\]. The inactive helmet (sham) contains only LEDs with power \< 1 mW, only serving to simulate the irradiation of the patient. All the patients will be submitted to 18 30-min LLLT sessions (active or sham condition), three times per week over six weeks. For safety, after the LLLT intervention, the patient will be asked about side effects between sessions.

### Neuropsychological assessment {#Sec15}

Patients will be assessed at baseline, one week after the end of the LLLT, and three months after the LLLT sessions. Each patient will follow the participation period as shown in Fig. [1](#Fig1){ref-type="fig"}.

Instruments:Beck Depression Inventory (BDI-II), used to assess depressive symptoms, classified as minimal (0--11 scores), mild (12--19), moderate (20--35), and severe (36--63) \[[@CR41], [@CR42]\];Beck Anxiety Inventory (BAI), used to assess anxiety symptoms, classified as minimal (0--7 scores), mild (8--15), moderate (16--25), and severe (26--63) \[[@CR42]\];Trail Making Test A and B (TMT A and TMT B), used to measure attention, speed, and mental flexibility. In TMT A, the patient is instructed to draw a line from 1 to 2, 2 to 3, and so on. In TMT B, the patient switches between numbers and letters, drawing a line from 1 to A, A to 2, 2 to B, and so on. On both forms A and B, the patients perform a sample before the real test. The patient is instructed to perform as fast as he/she can \[[@CR43]\];Stroop Test - Version Victoria, measuring cognitive control with each person can maintain a goal in mind and suppress a habitual response in favor of a less familiar one. The interference effect is determining by calculating the extra time required to name colors (Card 3) in comparison to the time required to name colors in the control task (Card 1) \[[@CR43], [@CR44]\];Controlled Oral Word Association Test (COWAT), used to evaluate the spontaneous production of words under restricted search conditions (verbal association fluency). For the phonemic fluency task, the patient must provide orally as many words as possible beginning with the letters F, A, and S for 1 min for each letter. For the semantic fluency task, the patient is asked to produce as many animals' names as possible within 1 min. The total correct is the sum of all admissible words for the semantic category \[[@CR43]\];Five-point test, this test requires preproduction of novel designs under time constraints (3 min). The score is calculated including the total number of unique designs and the number of repeated designs (perseverations) \[[@CR45]\];Symbol Digit Modalities Test (SDMT) oral version, the test is used to assess divided attention, visual scanning, tracking, and speed. The examiner records the numbers that correspond with symbols. The number of correct substitutions within the 90-s interval is the score of the task \[[@CR46], [@CR47]\];Rey Auditory Verbal Learning Test (RAVLT), measures immediate episodic memory, learning, susceptibility to interference, and recognition memory. A list of 15 nouns (list A) is read aloud to the patient, for five consecutive trials, each followed by a free-recall test. An interference list of 15 words (list B) is presented, followed by a free-recall test of that list. Immediately after this, delayed recall of list A is tested (Trial 6), and after 20 min (Trial 7), without further presentation of those words. The recognition is performed by presenting 50 words containing words from lists A, B, and new words, and the patient needs to identity the words from list A \[[@CR43], [@CR48]\];Sequence Numbers and Letters (Wechsler subscale - WAIS-III), used to evaluate working memory, random numbers, and letters is presented orally to the patient and must be mentally organized and immediately reported to the examiner with the following rule: first the crescent numbers then the letters (in alphabetical order). In test difficulty increases the patients correctly perform the task \[[@CR49]\];Digit Span (DS) Forward and Backwards (WAIS-III), the DS assesses working memory. For the DS forward, the patient hears carefully a sequence of numbers and must repeat it immediately in the same sequence as previously presented. For the DS backwards, the patient must repeat the sequence inversely. In both conditions the number of numbers presented increases as the patient hits two corrects scores from the same span \[[@CR49]\];Rey-Osterrieth Complex Figure Test (ROCF), the purpose is to assess visual--spatial constructional ability and visual memory. The patient is required to copy the ROCF, and after 3 and 30 min, a white sheet is given to the patient, and asked to draw the amount of information retained over time \[[@CR50], [@CR51]\].

Primary outcome {#Sec16}
---------------

Inhibitory attentional control (time score) measured by Stroop test. The Stroop test is known to be an accurate assessment of executive function in mild to moderate TBI \[[@CR52]\].

Secondary outcomes {#Sec17}
------------------

Verbal and visuospatial episodic memory;Executive functions (working memory, verbal and visuospatial fluency, attentional processes);Anxiety and depressive symptoms.

Sample size {#Sec18}
-----------

Based on the previous pilot study \[[@CR37]\] that analyzed the cognitive function of patients with TBI after repetitive sessions of RED/Near-infrared LED treatment. Considering the improvement on Stroop test of 1 standard deviation (SD) related to the baseline, the level of significance of 0.05 and the power of 80%, 16 patients per group was estimated. Considering the rate of 15% of drop-outs, we added two participants per group, ending with a total sample of 36.

Randomization {#Sec19}
-------------

All eligible recruited patients will be randomly divided into two groups with a 1:1 ratio and blocks of four and six performed by the co-investigator through the randomization list (randomization.com). The randomization list will be kept in safe storage with the co-investigator responsible for the stimulation sessions. She will provide the allocation concealment assignment for the patients. No information about the assigned group will be given for the patient or to the research assessor.

Blinding and allocation concealment {#Sec20}
-----------------------------------

Both helmets, the active and the sham, are identical in size, color, and weight. The active helmet activates the red light when plugged; however, the sham helmet cannot provide visible light. The patient is not able to see the light and there is no hit during the active stimulation that can suggest the type of intervention. The unblinded investigator is the person in charge of performing the stimulation. Both assessor researcher and patient will be blind for the type of intervention.

During the study, telephone contact can be used to maintain patient adherence to the trial. This study involves the participation of a research committee not directly related to the allocation of the patients. They can remove the blinding if any relevant situation may rise involving any clinical condition, adverse event, or even abandonment of the patient.

Safety considerations and adverse events {#Sec21}
----------------------------------------

Phase 1 trials and animal studies showed evidence related to the safety of the LLLT \[[@CR24], [@CR26], [@CR53]\]. Although there are few studies in clinical patients, no side effects were reported using photostimulation and LLLT \[[@CR17], [@CR22], [@CR37], [@CR38], [@CR54]--[@CR57]\]. For safety, the LLLT will be applied by a registered nurse or a trained clinician.

Ethical approval and consent to participate {#Sec22}
-------------------------------------------

The protocol was approved by CONEP Resolution 466/2012, which regulates scientific research involving human beings in Brazil. It follows the ethical principles of Declaration of Helsinki for medical research involving human subjects.

Statistical analysis {#Sec23}
--------------------

Intention-to-treat and per-protocol analyses will be performed for the primary and secondary outcomes. Missing data will be analyzed with regression imputation, considering the confounders (months of the trauma, years of age, schooling years, and depressive symptoms). Patients that did not receive 60% of the total stimulation will be considered non-adherent and analyzed as per-protocol.

Means and standard deviation will be used to represent data with normal distribution and medians and quartiles to describe non-normally distributed data. Two-way ANOVA (2 groups × 3 times) with repeated measures (for parametric variables) or the Kruskal--Wallis test (for non-parametric variables) will be used for the analysis of the TLT effects obtained in the three timelines: baseline, one week, and three weeks after the intervention. The Bonferroni correction for multiple comparisons will be employed as a post-hoc test. The effect size will be calculated based on the difference between means of the pre-intervention and post-intervention evaluations and will be expressed with respective 95% confidence intervals. Parametric Student's t-test or a Mann--Whitney *U* test for non-parametric data will be employed to assess between-group (active and sham helmet) differences in age, height, weight, and body mass index (BMI), time of TBI injury, level of education, and Glasgow Coma Scale at admission on the emergency room. For all effects, a *p* value \< 0.05 will be considered indicative of statistical significance. The data will be organized and tabulated using the Statistical Package for the Social Sciences (SPSSv.19.0).

Discussion {#Sec24}
==========

The present study is designed to evaluate the effects of 18 sessions of LLLT over cognition, in patients with chronic moderate and severe TBI. Our primary hypothesis is that the sessions of active LLLT will improve attention (at least 1 SD) measured by Stroop test compared to the placebo group (sham LLLT). Our secondary hypothesis is that the active group will improve in all domains assessed by the neuropsychological battery, including cognition and mood, compared to placebo group.

LLLT can modulate many biological effects penetrating the scalp into the brain \[[@CR25]\], playing a role improving the outcome of the patients in two different ways, depending on the stage of the trauma. In the acute phase after TBI, the initial neuronal injury occurs instantly and oftentimes causes irreversible damage to the central nervous system, due to impairment of neuronal cell functions, including mitochondria, and glia cells \[[@CR18], [@CR58]\]. The disruption of neuronal circuitry causes loss of connectivity between different areas of the brain and can negatively impact neural regeneration, leading to dysfunctional interactions. In the secondary stage after the trauma, other changes may occur, including release of neurotransmitters, decreased glucose utilization, lactic acid accumulation, reduced activity of ATP-reliant ion pumps, increased release of glutamate, Ca2 + −induced depolarization, and excitotoxicity \[[@CR21], [@CR58]\].

Previous studies showed improvement on cognition including attentional process and episodic memory after repetitive sessions of LLLT in patients with TBI \[[@CR17], [@CR37]\]. It seems that the LLLT decreases the inflammatory response, helping the neuroprotection after TBI. This process leads to increases on the ATP, cellular energy, and blood flow, decreasing the metabolic process. In summary, the LLLT seems to increase the intercellular synapses, acting as a possible treatment after acute and chronic TBI \[[@CR37], [@CR59]--[@CR61]\].

Other studies reported the effects of the LLLT in another sample. Lampl et al. \[[@CR34]\] used the LLLT in patients with ischemic stroke and showed that infrared wavelength therapy was safe and effective in the experimental group compared to the control groups when treatment was started 24 h after the onset of stroke. Another study with psychiatric patients showed that seven (out of ten) patients with severe cases of depression and anxiety presented symptom remission after two weeks elapsed with four LLLT applications in the prefrontal region, which did not occur with the control group \[[@CR62]\]. Likewise, LLLT has been demonstrated as a safe and effective technique in significantly improving the memory, attention, and mood performance of healthy people \[[@CR63]\]. Overall, we expect that our trial can complement previous findings, as an effective low-cost therapy to improve cognitive sequel in patients with chronic TBI.

Trial status {#Sec25}
============

The randomization of patients was started on January 2015. The inclusion of participants is ongoing, with 12 patients completing the assessment, four patients in the second assessment and two patients in the first assessment. We expect to conclude the study by 5 October 2018.
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